

## Product Update:

**adalimumab 40mg solution for injection in pre-filled syringe or pen,  
40mg/0.8ml solution for injection vial for paediatric use (Humira®) (No:881/13)  
AbbVie Ltd**

07 June 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**adalimumab (Humira®) solution for injection** is accepted for restricted use within NHS Scotland.

**Indication under review:** in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years.

**SMC restriction:** use within specialist rheumatology services (including those working within the network for paediatric rheumatology). Combination treatment with methotrexate is the primary option. Doses in this age group are based on body surface area calculations.

The Scottish Medicines Consortium has previously accepted this product for restricted use for this indication in children and adolescents aged 4 to 17 years.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 15 April 2013.*

**Chairman  
Scottish Medicines Consortium**

*Published 08 July 2013*